Resources from the same session
1O - Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
Presenter: JORDI REMON MASIP
Session: Proffered Paper 1
Resources:
Abstract
Slides
Webcast
2O - Phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR mutant non-small cell lung cancer (NSCLC): Analysis of adverse events (AEs)
Presenter: Saumil Ghandi
Session: Proffered Paper 1
Resources:
Abstract
Invited Discussant 1O and 2O
Presenter: Daniel Shao Weng Tan
Session: Proffered Paper 1
Resources:
Slides
Webcast
Q&A
Presenter: Daniel Shao Weng Tan
Session: Proffered Paper 1
Resources:
Webcast
3O - Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC
Presenter: Pilar Garrido Lopez
Session: Proffered Paper 1
Resources:
Abstract
Slides
Webcast
4O - Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC
Presenter: David Waterhouse
Session: Proffered Paper 1
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: Heather Wakelee
Session: Proffered Paper 1
Resources:
Webcast